Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person14
Opus Genetics, Inc.
Company
Fulgent Genetics, Inc.
Company
MYRIAD GENETICS INC
Company
GENESCO INC
Company
Neuronetics, Inc.
Company
INTELLINETICS, INC.
Company
CYTOKINETICS INC
Company
10x Genomics, Inc.
Company
ORAGENICS INC
Company
SOPHiA GENETICS SA
Company
Genvor Inc
Company
Genasys Inc.
Company
Genprex, Inc.
Company
Bionano Genomics, Inc.
Company
Primary record16
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-11-05.
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-10-27.
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-10-27.
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-10-27.
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-10-27.
BlackRock, Inc. filed SCHEDULE 13G
0002012383-26-003823.txt : 20261027 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0002012383 XXXXXXXX LIVE Common Stock 09/30/2026 0001228627 OPUS GENETICS INC 67577R102 8 Davis Drive Durham NC 27713 Rule 13d-1(b) Bl
Opus Genetics, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have
Opus Genetics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 15, 2026, Opus Genetics, Inc. (the Company ) issued a press release regarding the Company s October 14, 2026 presentations at the Retina in Rio 2026 conference held in Rio d
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-09-11.
Opus Genetics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 11, 2026, Opus Genetics, Inc. (the “Company”) issued a revised version of the Company’s data presentation, which was initially used in connection with its investor confere
Opus Genetics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 9, 2026, Opus Genetics, Inc. (the “Company”) issued a press release and held an investor conference announcing clinical data from Cohort 1 of the Company’s ongoing Phase 1
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-09-08.
Opus Genetics, Inc. filed 4
SEC form 4 filed by Opus Genetics, Inc. (CIK 1228627) on 2026-09-08.
Longeveron Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Longeveron Inc. (the Company ) has appointed Nirav S. Jhaveri
Opus Genetics, Inc. filed SCHEDULE 13G/A
on August 6, 2026, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 9,233,710 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Commo
Opus Genetics, Inc. filed SCHEDULE 13G/A
on August 6, 2026. 7.3% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii